Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLPG5101 in treatment-refractory active systemic lupus erythematosus
NL-OMON58939Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Nov 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, single-arm trial of GLPG5101 in systemic lupus erythematosus (SLE), sponsored by Galapagos NV. Started Nov 2023; status: completed.
02
Drugs
GLPG5101
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON58939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58939.